Lorlatinib

Category: Cancer



Lorlatinib Overview

Lorlatinib (PF-6463922) is an anti-neoplastic drug developed by Pfizer. It is an orally-administered small molecule inhibitor of ROS1 and ALK. In 2015, FDA granted Pfizer orphan drug status for lorlatinib for the treatment of non-small cell lung cancer.[1] Lorlatinib is able to cross the blood-brain barrier.[2] Clinical studies Several clinical trials are ongoing. A phase II trial comparing avelumab alone and in combination with lorlatinib or crizotinib for...

Read more Lorlatinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lorlatinib

Recent Lorlatinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lorlatinib
  • Tablet: 100mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lorlatinib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA